India's Cipla gets tentative U.S. nod for HIV tablets
MUMBAI (Reuters) - Indian drugmaker Cipla has received a tentative U.S. FDA approval for its HIV treatment tablets, which have a combination of lamivudine, nevirapine and zidovudine drugs, the drug regulator's website showed.
Cipla sells the combination drug under the brand name 'Duovir N' outside the United States.
The company plans to use a different brand name in the U.S. for this drug, S. Radhakrishnan, a director on Cipla board told Reuters.
(Reporting by Kaustubh Kulkarni; Editing by Anupama Dwivedi)
- Tweet this
- Share this
- Digg this
- British Muslims blame jihadi subculture after beheading video
- Trucks from aid convoy to Ukraine start crossing back into Russia |
- Shi'ite militia kill dozens of Iraqi Sunnis in mosque shooting
- U.S. says Russia must pull convoy from Ukraine or face more sanctions |
- U.S. hostage rescuers dropped from night sky, Syria activist says